anti-Solute Carrier Family 47, Member 1 (SLC47A1) Antibodies

Human Solute Carrier Family 47, Member 1 (SLC47A1) interaction partners

1. The studied SLC47A1 and SLC47A2 SNPs had no influence on the dose requirement or adverse effects of metformin.

2. genetic association studies in population in China: Data confirm that an SNP in an intron of SLC47A1 (rs2289669) is associated with hypoglycemic response to metformin in patients with newly diagnosed type 2 diabetes; differential increases in basal GLP1 plasma levels are also related to this SNP. (SLC47A1 = solute carrier family 47 member 1; GLP1 = glucagon-like peptide-1)

3. The impact of assay conditions on IC50 determination is negligible, kinetic characteristics differ among used test substrates, and substrate-dependent inhibition exists for MATE1 and MATE2-K, giving valuable insight into the assessment of clinically relevant MATE-mediated drug interactions in vitro.

4. Pazopanib inhibits OCT2, MATE1 and MATE2-K, which are involved in cisplatin secretion into urine, potentiating cisplatin toxicity.

5. The 5' CpG island of SLC47A1 acts as an enhancer for SLC47A1, and DNA methylation in the CpG island plays a role in interindividual differences in hepatic SLC47A1 expression.

6. The combination of ENT1, MATE1 and OCT2 SNPs may serve as a predictive and prognostic marker in metastatic colorectal carcinoma patients treated with TAS-102.

7. MATE1 is the major transporter for the cellular uptake of imatinib and crucial for the therapeutic success in CML patients. We suggest that the detailed analysis of MATE1 expression levels and mutations could be a predictor for the response to imatinib therapy.

8. This study did not identify any of these known SLC47A1 coding SNPs in the Xhosa individuals who participated in this study.

9. substrate identity exerts comparatively little influence on ligand interaction with MATE1.

10. MATE1 mRNA levels in peripheral blood cells were significantly higher in patients carrying the minor allele of rs2453579, but not rs2252281, compared to those with other genotypes

11. MATE1 polymorphisms were associated with hematological toxicity in non-small cell lung cancer patients.

12. MATE1 rs2289669 may be a significant determinant in the renal clearance of metformin in the case of transporter-mediated drug interactions

13. Disease progression according to RECIST was also more frequent in carriers of at least one polymorphic MATE1 A-allele (44%) as compared with homozygous carriers of the wild-type G-allele (12.5%) (P=0.07). OCT1 and MATE1 were not associated with PFS.

14. MATE1 sequesters organic cations within an intracellular compartment that has no influence on secretion in renal proximal tubules.

15. SLC47A1 rs2289669 G>A variants improve the glucose-lowering effect of metformin through slowing its excretion in type 2 diabetes populations.

16. MRNA levels of multidrug and toxin extrusion protein 1 (MATE1 or SLC47A1, encoded by 1 of the 11 genes) were significantly lower in patients with FILI.

17. MATE1 is a membrane transporter for quercetin.MATE1 was highly expressed in peroxisomes and the endoplasmic reticulum as well as in plasma membranes in the liver and intestine.

18. ADMA and L-arginine are substrates of human CAT2A, CAT2B, OCT2 and MATE1. Transport kinetics of CAT2A, CAT2B, and OCT2 indicate a low affinity, high capacity transport, which may be relevant for renal and hepatic elimination of ADMA or L-arginine

19. The results confirmed that OAT1, OAT3, OCT2, MATE1, and MATE2-K were coexpressed in tubular epithelial cells.

20. Decreasing expression of OCT3 and MATE1 in human placenta indicates these transporters may play a role in fetal protection preferentially at earlier stages of gestation.

Mouse (Murine) Solute Carrier Family 47, Member 1 (SLC47A1) interaction partners

1. Tissue concentration based investigations using [(11)C]metformin by PET enables the functional analysis of MATEs in the liver and kidneys

2. Mate1 mRNA expression was decreased in mice with either the ob/ob model or the methionine/choline deficiency model of nonalcoholic steatohepatitis.

3. MATE1 was highly expressed in peroxisomes and the endoplasmic reticulum as well as in plasma membranes in the liver and intestine.

4. [(11)C]Metformin may be useful as a PET probe to non-invasively study the in vivo function of hepatobiliary transport and drug-drug interactions, mediated by MATE1 in future clinical investigations.

5. Twelve transmembrane helices form the functional core of mammalian MATE1 (multidrug and toxin extruder 1) protein.

6. Homozygous MATE1 variant could be one of the risk factors for metformin-induced lactic acidosis.

7. MATE1 mediates the efflux of cisplatin and is involved in cisplatin-induced nephrotoxicity.

8. The purpose of this study was to evaluate the effects of heterozygous MATE variants on the disposition of metformin in mice and humans.

9. mMATE1 is polyspecific H(+)/(organic cation)OC exchanger. Unexpectedly wide distribution of mMATE1 suggests involvement in diverse biological functions other than excretion of OCs from the body. (Multidrug and toxin extrusion 1, MATE1)

10. mMATE1b is a functional variant of mMATE1 and seems to be the true counterpart to other MATE1 transporters

11. MATE1 mRNA levels were highest in the kidney, where male expression was higher than female.

12. This is the first report to demonstrate an essential role of MATE1 in systemic clearance of metformin.

Rabbit Solute Carrier Family 47, Member 1 (SLC47A1) interaction partners

1. MATE1 has an external COOH terminus, consistent with a 13-helix topology, which may influence transporter turnover.